Glucagon like Peptide 1 News and Research

RSS

New discovery in beta-cell pathway shows potential to improve effectiveness of diabetes drugs

Over the past 15 years, University of Alabama at Birmingham endocrinologist Anath Shalev, M.D., has unraveled a crucial biological pathway that malfunctions in diabetes.

8 Nov 2017

Increased enzyme production by the liver causes fatty liver, obesity and insulin resistance

In mice that are given a high-fat diet, an increased production of the enzyme DPP4 by the liver promotes an increase in body fat, the development of fatty liver disease and insulin resistance.

24 Aug 2017

Common obesity and diabetes drug could be used as novel way to lower brain pressure

Research led by the University of Birmingham, published today in Science Translational Medicine, has discovered that a drug commonly used to treat patients with either obesity or Type II diabetes could be used as a novel new way to lower brain pressure.

23 Aug 2017

Diabetes drug shows promise as Parkinson’s treatment

A drug commonly used to treat diabetes could help people living with Parkinson’s disease, say researchers.

7 Aug 2017

Gene-therapy administered through skin transplants could enable treatment of many diseases

A research team based at the University of Chicago has overcome challenges that have limited gene therapy and demonstrated how their novel approach with skin transplantation could enable a wide range of gene-based therapies to treat many human diseases.

3 Aug 2017

Researchers capture first cryo-EM snapshots of key cellular receptor in action

Researchers at the University of Michigan, Stanford University and biotech company ConfometRx have captured the first cryo-electron microscopy snapshots of a key cellular receptor in action.

25 May 2017

Timing of carbohydrate intake plays role in blood glucose regulation for men with prediabetes

According to a nutrition study led by the German Institute of Human Nutrition, a partner of the German Center for Diabetes Research, the so-called internal clock also influences how people with impaired glucose metabolism react to carbohydrate-rich food.

9 Mar 2017

Epigenetic changes favor development of fatty liver in humans and mice

Mice with a strong tendency to obesity already exhibit epigenetic changes at six weeks of age, inducing the liver to amplify its production of the enzyme DPP4 and release it into the circulation. Over the long term, this favors the development of a fatty liver.

9 Jan 2017

Platypus venom shows potential for new diabetes treatments

Australian researchers have discovered remarkable evolutionary changes to insulin regulation in two of the nation's most iconic native animal species - the platypus and the echidna - which could pave the way for new treatments for type 2 diabetes in humans.

29 Nov 2016

Results of high-impact clinical trials could improve kidney-related medical care

The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented at ASN Kidney Week 2016, November 15-20 at McCormick Place in Chicago, IL.

21 Nov 2016

Study shows diabetes drug ineffective in improving condition of patients with advanced heart failure

In an attempt to correct defects in the energy generation that contribute to poor pump function among heart failure patients, researchers examined whether the diabetes drug liraglutide, could improve the condition of patients with advanced heart failure.

2 Aug 2016

FDA approves new injection to improve blood sugar levels in adults with type 2 diabetes

The U.S. Food and Drug Administration approved Adlyxin (lixisenatide), a once-daily injection to improve glycemic control (blood sugar levels), along with diet and exercise, in adults with type 2 diabetes.

28 Jul 2016

Liraglutide cardioprotective in high-risk Type 2 diabetes patients

Findings of the LEADER trial show that liraglutide treatment may confer a reduced risk of cardiovascular events in patients with Type 2 diabetes and a high vascular risk.

15 Jun 2016

Liraglutide enhances high-dose insulin treatment in Type 2 diabetes

The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.

12 Jun 2016

New technique could help reduce chances of drug failure during later stages of clinical trials

An approach that could reduce the chances of drugs failing during the later stages of clinical trials has been demonstrated by a collaboration between the University of Cambridge and pharmaceutical company GlaxoSmithKline.

2 Jun 2016

Study helps discover new treatments for type 2 diabetes in men with low testosterone

Doctors have long known that men with low testosterone are at greater risk for developing type 2 diabetes. For the first time, researchers have identified how testosterone helps men regulate blood sugar by triggering key signaling mechanisms in islets, clusters of cells within the pancreas that produce insulin. The findings, co-authored by Tulane University researchers, are published in the journal

29 Apr 2016

GLP-1 receptor agonist may benefit high-risk diabetes

Research shows that using a glucagon-like peptide-1 receptor agonist instead of a rapid-acting insulin analogue at mealtimes can reduce glycaemic variability in high-risk patients with Type 2 diabetes.

26 Apr 2016

Newly developed light-activated tool could pave way for new generation of anti-diabetic drugs

Researchers have developed a light-activated tool to show how drugs need to be adapted to combat type 2 diabetes.

12 Apr 2016

Liraglutide drug makes highly desirable foods less appealing to people

Understanding the motivations that drive humans to eat is an important consideration in the development of weight loss therapies. Now a study led by researchers at Beth Israel Deaconess Medical Center helps explain how the diabetes and weight loss drug liraglutide acts on brain receptors to make enticing foods seems less desirable.

5 Apr 2016

Drug combination improves glucose control in Type 2 diabetes patients

A multinational clinical trial led by UT Southwestern Medical Center and others found that injection of a new long-acting insulin combined with another drug improves glucose control in patients with Type 2 diabetes and, additionally, is associated with weight loss.

2 Mar 2016